Design Therapeutics, Inc. (DSGN) financial statements (2022 and earlier)

Company profile

Business Address 6005 HIDDEN VALLEY ROAD
CARLSBAD, CA 92011
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:384,100
Cash and cash equivalents298,569
Short-term investments170,990
Other undisclosed cash, cash equivalents, and short-term investments(85,459)
Receivables110
Prepaid expense1,254
Other current assets7
Other undisclosed current assets(36)
Total current assets:385,435
Noncurrent Assets
Operating lease, right-of-use asset3,614
Property, plant and equipment1,508
Total noncurrent assets:5,122
TOTAL ASSETS:390,557
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,283
Accounts payable1,620
Accrued liabilities3,663
Total current liabilities:5,283
Noncurrent Liabilities
Long-term debt and lease obligation3,144
Operating lease, liability3,144
Other undisclosed noncurrent liabilities(3,144)
Total noncurrent liabilities:3,144
Total liabilities:8,427
Stockholders' equity
Stockholders' equity attributable to parent382,130
Common stock6
Additional paid in capital429,824
Accumulated other comprehensive loss(244)
Accumulated deficit(47,456)
Total stockholders' equity:382,130
TOTAL LIABILITIES AND EQUITY:390,557

Income statement (P&L) ($ in thousands)

12/31/2021
Operating expenses(35,831)
Operating loss:(35,831)
Nonoperating income
(Other Nonoperating income)
298
Net loss available to common stockholders, diluted:(35,533)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(35,533)
Comprehensive loss:(35,533)
Other undisclosed comprehensive loss, net of tax, attributable to parent(400)
Comprehensive loss, net of tax, attributable to parent:(35,933)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: